SPS
TBPH icon

Susquehanna Portfolio Strategies’s Theravance Biopharma TBPH Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$492K Buy
28,924
+4,892
+20% +$81K 0.01% 668
2026
Q1 		$390K Sell
24,032
-19,318
-45% -$342K 0.01% 798
2025
Q4 		$811K Buy
43,350
+29,313
+209% +$486K 0.01% 685
2025
Q3 		$205K Buy
+14,037
New +$177K ﹤0.01% 981
2024
Q1 		– Sell
-13,317
Closed -$150K – 950
2023
Q4 		$150K Buy
+13,317
New +$134K ﹤0.01% 962

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Susquehanna Portfolio Strategies's TBPH Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its Theravance Biopharma (TBPH) stake by 20% in Q2 2026, buying an estimated $81K and bringing the position to 28,924 shares worth $492K. The position accounts for 0.01% of the portfolio, ranked #668.

Susquehanna Portfolio Strategies first reported a position in TBPH in Q4 2023 and has held it in 5 quarters since. The position peaked at $811K in Q4 2025. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Susquehanna Portfolio Strategies held 28,924 shares of Theravance Biopharma worth $492K as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 4,892 Theravance Biopharma shares in Q2 2026, an estimated $81K.
  • Theravance Biopharma made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #668 holding.
  • Susquehanna Portfolio Strategies first reported a position in Theravance Biopharma in Q4 2023 and has held it in 5 quarters since.
  • Susquehanna Portfolio Strategies's Theravance Biopharma position peaked at $811K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.